UK markets open in 5 hours 57 minutes

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.0400-0.0100 (-0.95%)
At close: 04:00PM EST
1.0500 +0.01 (+0.96%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.0500
Bid1.0400 x 36200
Ask1.0600 x 34100
Day's range1.0400 - 1.1100
52-week range0.9100 - 6.8700
Avg. volume4,516,305
Market cap134.427M
Beta (5Y monthly)2.29
PE ratio (TTM)N/A
EPS (TTM)-1.1200
Earnings date05 Mar 2024 - 11 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.02
  • Business Wire

    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., January 17, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on January 10, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 67,500 shares of its common stock to one new employee, consisting of stock options to purchase 45,000 shares of common stock and restricted stock units ("RSUs") covering 22,500 shares of

  • Zacks

    Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?

    Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

  • Business Wire

    Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

    CAMBRIDGE, Mass., January 09, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics and receipt of US FDA Fast Track Designation for SER-155 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th. VOWST, the first FDA approved orally administered microbiome therapeutic, received FDA approval in April of 2023 and is indica